Why Citi just became even more bullish on the CSL share price

The CSL Limited (ASX: CSL) share price could be great value at current levels.

That’s the view of one leading broker, which has become even more bullish on the biotherapeutics giant’s shares this week.

What is the broker saying about the CSL share price?

According to a note out of Citi, its analysts have retained their buy rating and lifted their price target on the company’s shares to $345.

Based on the current CSL share price of $296.85, this implies potential upside of 16% for investors over the next 12 months.

Why is Citi bullish?

Citi has become even more bullish on CSL following the release of results from industry rivals Grifols and Takeda. Its analysts note that these results are pointing to major improvements in trading conditions for the plasma market.

In fact, everything appears to be falling into place with demand and pricing strengthening and donor costs softening. It is partly for this reason that CSL is the broker’s top ANZ healthcare pick.

Citi explained:

Results from Grifols (June HY) and Takeda (June Q) show continued improvement overall in the operating environment for the plasma industry – this is as we anticipated and supportive of our CSL forecasts. The key points from the results were: 1) Demand is very strong, and prices are up mid-single digit, showcasing the pricing power of plasma companies; 2) Plasma collections are now well above pre-covid levels; 3) Plasma donor fees are coming down, helping margins.

CSL is our top pick – Australia/NZ Healthcare.

Outside this, the broker expects “the settlement of the Vifor deal, and a positive outlook on plasma collection at the FY22 result will continue to see the share price outperform over the next 12 months.”

All in all, Citi appears to believe that this could make now an opportune time to snap up CSL shares before it is too late.

The post Why Citi just became even more bullish on the CSL share price appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

See The 5 Stocks
*Returns as of July 7 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/dICpk3b

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s